AIM ImmunoTech Inc.·Healthcare

Seeing Machines Ltd (AIM:SEE, OTC:SEEMF, FRA:M2Z) told investors it has so far found no evidence of unauthorised access to its systems or data, after investigating an alleged cyber threat flagged to the company around 10 days ago. The AIM-listed transport safety technology group said a third party had named it online alongside claims that some company data had been accessed.

Impax Asset Management (AIM:IPX, FRA:LW4) shares dropped in Friday morning's deals, losing 21% to 98.68p, as the firm reported assets under management fell 8% over its fiscal second quarter to £22.3 billion, as continued client redemptions prompted the AIM-listed specialist investor to guide for lower full-year revenue. Net outflows totalled £2.01 billion in the three months to 31 March 2026, driven principally by listed equities, while performance, market movements and foreign exchange added just £83 million.

Union Jack Oil PLC (AIM:UJO, OTCQB:UJOGF, FRA:1UJ0) has announced that the Crossroads well in southern Oklahoma is set to be spudded on or around 16 April, giving investors a near-term drilling catalyst on a project where the company already has its funding in place. The AIM-listed group holds a 43% interest in Crossroads, with Reach Oil and Gas acting as operator, and, Union Jack said its share of drilling costs has already been funded, de-risking the immediate cash call ahead of operations.

Cavendish sees very substantial upside for 88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ) after the AIM-listed explorer secured access to a 3D seismic dataset over its Kad River East acreage in Alaska, with the broker reiterating a Buy rating and 19.8p target price (compared to the current price of 1.5p per share). The stockbroker, in a note, highlighted that the firm's newly licensed Kad River 3D survey covers the entirety of the recently acquired leases and strengthens the case for an active, multi-reservoir petroleum system already indicated by legacy 2D seismic and historic well data.

Sorted Group Holdings PLC (AIM:SORT) saw its share price halve to 10p after it unveiled plans to dispose of its main operating business for £1 and become an AIM cash shell, just two years after its arrival via reverse takeover. The AIM-listed software group said it intends to sell Sorted Group Ltd for a nominal consideration, subject to shareholder approval later this month.

The AIM-listed rare earths company upsized its placing after strong demand, though shares fell back on dilution concerns. Shares in Mkango Resources Ltd (AIM:MKA, TSX-V:MKA, OTC:MKNGF), the rare earths developer, fell 13% to 33.6p on Wednesday despite the company completing a fundraise that was significantly oversubscribed and upsized from its original £10 million target to £12.5 million.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.